Robert L. Crutchfield is Managing Director of BrightEdge Venture Fund. BrightEdge is the American Cancer Society's strategic venture philanthropy platform, targeting investments that advance the commercialization of advanced therapies to treat, detect, and prevent all types of cancer. Prior to the BrightEdge Fund, Bob was a Sr. Partner at Harbert Growth Partners where he led the healthcare practice. His investments that have been realized where he served as a board member or board observer include Shipt - acquired by Target in 2017, Wellcentive - acquired by Royal Philips in 2016, nContact - acquired by Atricure in 2014 and Novamin - acquired by GSK in 2009. He also serves on the boards of the Southeastern Medical Device Association, the Southern Capital Forum, the Birmingham Innovation Depot, the Atlanta Global Center for Medical Innovation, HealthSouth Connect, and the True Vine Foundation. He is a Board Observer at Castle Biosciences, Inc and Freenome, Inc. Bob is a graduate of the University of Georgia and holds Bachelor of Science degrees in Political Science and Chemistry.